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ABSTRACT
Diabetes mellitus is a worldwide epidemic disease that eventually advances to a chronic stage and affects different vital organs by intensifying the 
underlying pathological factors, and through the remodeling of the tissues by the generation of reactive oxygen species leading to the development 
of respective organ failure. Two such complications are painful neuropathy and cardiomyopathy; both of which are common and progressive 
complications of diabetes. The symptoms of peripheral neuropathy include tingling, burning, lancinating pain, hyperesthesia, and allodynia. The course 
of the disease progression may vary from intermittent, mild symptoms to severe chronic, and daily pain; which culminates into poor quality of life. 
Another complication of diabetes mellitus, diabetic cardiomyopathy, is defined as a ventricular dysfunction disorder that occurs in diabetic patients. 
The development of the disease is characterized by a hidden subclinical period, during which cellular, structural changes and abnormalities lead to 
diastolic dysfunction, followed by systolic dysfunction, and terminating into heart failure. Left ventricular hypertrophy, metabolic abnormalities, 
extracellular matrix changes, small vessel disease, cardiac autonomic neuropathy, insulin resistance, oxidative stress, and apoptosis are the most 
important pathological advancements that lead to diabetic cardiomyopathy. Various pharmaceutical agents from different pharmacological categories 
have been proposed for the symptomatic treatment of painful diabetic neuropathy; however, it is a herculean task to select a drug due to the wide 
range of choices and lack of consistent guidelines for treatment. Similarly, treatment of cardiomyopathy is based on the general therapeutic rules 
of management of heart failure and no specifications have yet been addressed for this condition. Therefore, more studies are required to improve 
our knowledge of these complex syndromes. From this perspective, this review is designed to delineate a general overview of neuropathy and 
cardiomyopathy, referring to the conventional therapies in use and possible unconventional, natural, herbal, and safe treatments for both the above-
mentioned complications of diabetes.
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INTRODUCTION
Statistical insight to diabetes mellitus
Diabetes mellitus is one of the most common, increasing, and serious 
public health problems among all the metabolic disorders worldwide 
both for the disease itself and for associated severe secondary 
complications. As per data recorded and updated to March 2013, 
provided by the World Health Organization and also reported by one of 
the Lancet journals (Diabetes –a global threat; 2011), the statistical data 
related to diabetes mellitus are alarming, there has been an increased 
incidence of diabetes cases from 1980 to 2008 when number of patients 
increased from 153 million to 347 million people worldwide suffering 
with diabetes mellitus. Moreover, it is predicted that this amount will 
increase to 380 million in 2025, representing 7.1% of the world’s 
adult population [1-4]. On the basis of investigations carried by Chang 
et al. 2013; Espelt et al. 2013; a total of 57 million deaths occurred in 
the World during 2008, of which 36 million (63%) were due to non-
communicable diseases, among these, diabetes alone caused 1.3 million 
deaths. Therefore, it is projected as a global health problem. Today, over 
90% of diabetic patients are diagnosed with type 2 diabetes mellitus 
(T2DM), with an increased incidence in recent years probably due to 
an increased prevalence of its main risk factors (obesity and sedentary 
life). Nephropathy, retinopathy, cardiomyopathy, and peripheral 
neuropathy are all recognized as important complications in about 50% 
of diabetes mellitus patients, mostly with improper glycemic control or 
unsuccessful management of disease [5-10].
DIABETIC PERIPHERAL NEUROPATHY
The International Association for the Study of Pain defines neuropathic 
pain as “pain resulting from disease or damage of the peripheral or 
central nervous systems, and from dysfunction of the nervous system. 
Neuropathic pain could be of many types such as paresthesias (numbness 
or tingling), dysesthesias (electric shock phenomenon), hyperesthesia 
(increased sensitivity to mild painful stimuli), hyperalgesia (increased 
sensitivity to normally painful stimuli), hyperpathia (pain produced by 
subthreshold stimuli), spontaneous pain, and allodynia (pain produced 
by normally non-painful stimuli. Diabetic peripheral neuropathy is 
characterized by symptoms such as pain, tingling, or numbness, loss of 
feeling in the hands, arms, feet, and legs. Painful neuropathy is common 
and in a few cases enfeebling complication of diabetes. The clinical 
trials conducted on patients suffering from type II diabetes (Davies 
et al. 2006; Ziegler et al. 2009) concluded that approximately one in 
four people with diabetes might be affected by chronic neuropathic 
pain. Patients often complain of symptoms such as discomfort, typically 
starting in the distal feet, but progressing proximally over time. Other 
symptoms such as numbness, tingling, burning, aching, electric shocks, 
or lancinating pain have also been observed, as stated in a review by 
Huizinga and Peltier, 2007. The body parts often affected include the 
legs, arms, hands, and fingers. The pain may be constant or intermittent, 
and there may be associated nocturnal worsening. Patients may also 
experience allodynia, when non-painful stimuli also become painful or 
hyperesthesia, when normally painful stimuli become excruciatingly 
painful [11-15].
CURRENT TREATMENT APPROACHES FOR DIABETIC PERIPHERAL 
NEUROPATHY
Although treatment of pain is critical to improvize the quality of life, 
it must be considered only one aspect of overall cure. Symptomatic 
management of neuropathy is altogether apart from treatment regimen 
for the disease itself, and therefore, aggressive treatment of underlying 
diabetes remains paramount as only then the patients can be completely 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i9.18785
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cured. Control of blood pressure, lipids, and other microvascular risk 
factors are necessary for effective long-term management of diabetes. 
There are a few medications which have been vetted in large and 
randomized on the basis of placebo-controlled or head-to-head clinical 
trials. Interpretation of the available data can be challenging because 
variables such as dosing, duration of treatment, and the definition of 
successful treatment may vary among studies. As stated in a study 
conducted by Gore et al. 2008, certain recommendations of guidelines 
and consensus statements available often differ, and many medications 
have adverse effects or interactions with medications used to treat 
diabetes. There are older medications, such as tricyclic antidepressants, 
which are commonly used to treat painful diabetic neuropathy but have 
not been tested in randomized clinical trials for this condition. These 
older medications may be excluded from recommended guidelines 
which use strict criteria, given their potential efficacy and utility. Hence, 
a report by Van et al.; 2009, states that due to these limitations, the 
actual implementation of treatment for painful diabetic neuropathy 
may prove daunting to clinicians and likely contributes to patients 
remaining untreated or undertreated [16-19].
A group of medications are suggested for use as first-, second-, and 
third-line treatment for painful diabetic neuropathy. These clinical 
suggestions are based on the criteria including evidence of efficacy, 
safety, tolerability, drug interactions, and cost. The list of reviewed drugs 
is not claimed to be an encyclopedia of all agents used to treat painful 
diabetic neuropathy, but have been rather compiled keeping a practical 
perspective of treatment in mind with substantial available evidence. 
First-line medications are supported by evidence from three or more 
randomized clinical trials in patients with painful diabetic neuropathy, 
while second-line medications are supported by evidence from two 
randomized clinical trials in patients with this condition. Third-line 
medications are commonly used to treat painful diabetic neuropathy 
and are supported by evidence from two or more randomized clinical 
trials in patients with this condition but also have conflicting data 
reported. Third-line medications offer treatment options for patients 
who have either not tolerated or have been unable to take first- and 
second-line drugs [20-22].
CLINICAL TRIALS ON DIABETIC PERIPHERAL NEUROPATHY [23-41] 
(TABLE 1)
Clinical case
Various clinical cases on treatment and management of diabetic 
neuropathy have been reported by Hovaguimian and Gibbons; 2011, 
one such case is mentioned below as a reference.
This is a clinical case of a 59-year-old woman suffering from type 2 
diabetes with complaints of numbness and pins for the past 2 years. 
Over the past 4 months, the symptoms have become increasingly 
bothersome. She has been treated in the past with gabapentin 300 mg. 
Her past medical history is remarkable for liver disease secondary to 
alcohol use with subsequent diabetes and thrombocytopenia. She has 
also had both hepatic encephalopathy and hepatorenal syndrome 
in the past. Her paresthesias have been persistent and may also be 
influencing her mood; therefore, symptomatic treatment may help 
improve her quality of life, and hence, the only first-line drugs without 
a contraindication in liver disease are pregabalin and gabapentin. As 
both gabapentin and pregabalin have similar mechanisms of action, 
it is, therefore, reasonable to repeat a trial of gabapentin first. The 
starting dose for gabapentin is 300 mg daily, and this dose can 
be titrated as tolerated to symptomatic relief or to 1200 mg thrice 
daily [42].
Diabetic cardiomyopathy is another complication of diabetes on 
which earliest data was reported four decades ago, hence, substantial 
information on its pathogenesis and clinical features had been 
accumulated. The relationship between diabetes mellitus and heart 
failure has been known for many years and includes several underlying 
pathogenesis. Leyden in 1881 first claimed that diabetic cardiomyopathy 
is a common complication of diabetes and one worthy of attention. In 
1888, Mayer reported that diabetes is a metabolic disorder that can lead 
to heart disease. Finally, the term “diabetic cardiomyopathy” was coined 
by Rubler in 1972, after conducting post-mortem studies in diabetic 
patients with heart failure who had no medical history of alcoholism, 
hypertension, coronary disease, and other structural heart diseases. 
Prolonged diabetes increases fatty acid metabolism, inhibits glucose 
oxidation and modifies intracellular signaling in the heart, leading 
to impairments in multiple steps of excitation-contraction coupling, 
inefficient energy production, and increased susceptibility to ischemia. 
Loss of normal blood capillaries and remodeling of the extracellular 
matrix are also involved in diabetic cardiomyopathy [43,44].
Oxidative stress has been long associated with the pathogenesis of 
diabetic cardiomyopathy. Prolonged hyperglycemia produces series 
of secondary transducers such as increase in reactive oxygen species 
(ROS), decreased nitrous oxide level, which leads to myocardial 
inflammation and endothelial dysfunction through PARP [poly 
(ADP-ribose) polymerase] inhibition. Anatomical and functional 
abnormalities of the vascular endothelium are commonly associated 
with diabetes [45].
PATHOPHYSIOLOGICAL CHANGES INVOLVED IN 
CARDIOMYOPATHY
Left ventricular hypertrophy (LVH)
The change in myocardial tissue due to diabetes is not an immediate 
pathogenesis but rather a consequence of long-term diabetes-
associated changes, such as obesity. As per the findings of Eguchi 
et al. [44], there is a significant interaction between diabetes and 
central obesity on the risk for development of LVH. Furthermore, 
obesity promotes concentric LVH independently of hypertension. 
The recent clinical findings explain the role of cytokines, produced 
by the expanded adipose tissue due to obesity, in the development 
of LVH. For example, leptin is linked to cardiac hypertrophy in obese 
humans and directly induces cardiomyocyte hypertrophy in vitro. The 
mechanisms by which leptin induces LVH is not fully characterized but 
might involve endothelin 1- mediated ROS generation. The strong heart 
study conducted in Native Americans, found that both men and women 
with diabetes had higher LV mass and wall thickness. Furthermore, in a 
multi-ethnic population, the likelihood of having LV mass that exceeds 
the 75th percentile is greater in patients with type 2 diabetes, after 
adjusting for various covariates including hypertension [46-49].
Oxidative stress
There are many experimental studies which have suggested that 
oxidative stress may play a critical role in the development of diabetic 
cardiomyopathy; however, the mechanism involved in ROS generation 
in diabetic hearts is not well understood. Clinical and pharmacological 
experimental studies have implicated that increased oxidative stress is 
associated with lipid overload; indeed, oxidative stress is increased in 
hearts isolated from the db/db mice model of type 2 diabetes, which 
are also characterized by cardiac lipid accumulation and increased 
mitochondrial fatty acid oxidation. Two different experimental models 
were designed to study the impact of fatty acids in ROS production. One 
model was designed on db/db mice, whereas the other on Akita mouse. 
In db/db hearts, oxidative stress is exacerbated in the presence of fatty 
acids, which we believe leads to mitochondrial uncoupling. Whereas 
the Akita mouse model of Type 1 diabetes does not exhibit increased 
mitochondrial ROS generation or shows any evidence of mitochondrial 
uncoupling despite increased rates of fatty acid oxidation. An important 
distinction between the hearts of Akita mice versus db/db or ob/ob 
mice is the presence of myocardial insulin resistance in obese models 
with insulin resistance, whereas in Type 1 diabetes models, insulin 
sensitivity is preserved. Interestingly, in mice with cardiac-specific 
deletion of insulin receptors, hydrogen peroxide production was 
increased, and mitochondria were uncoupled even at stage when 
myocardial fatty acid oxidation was reduced. This information indicates 
the possibility that myocardial insulin resistance may specifically 
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subject cardiac mitochondria to cause free radical overproduction 
through mechanisms that remain to be elucidated [50-52].
Interstitial fibrosis
Regan et al. stated in their study that diabetic cardiomyopathy 
is characterized by interstitial and perivascular fibrosis. Found a 
significant increase in collagen deposition around intramural vessels 
and between myofibers in heart biopsies form diabetic patients. In 
addition, a significant increase in collagen Type III but not Type I or 
VI was found in endomyocardial biopsies obtained from patients with 
Type 2 diabetes, who did not have significant coronary artery disease 
and hypertension. Similar to humans, some animal models with Type 2 
diabetes also exhibited an increase in cardiac fibrosis even before the 
onset of hyperglycemia which shows increased extracellular fibrosis and 
collagen deposition as reported in the pre-diabetic stage in OLETF rats, 
a genetic model of diabetes resembles human Type 2 diabetes [53-55].
CLINICAL DIAGNOSIS OF DIABETIC CARDIOMYOPATHY
The structural and functional changes observed in the left ventricle (LV) 
of the heart, excluding other heart diseases being responsible for these 
changes in a diabetic patient, that occur as a result of prolonged diabetes, 
form the basis for the diagnosis of diabetic cardiomyopathy. There 
are certain specific biomarkers and their respective detection tools 
which serve as the diagnostic techniques of diabetic cardiomyopathy 
(Table 2), tissue Doppler imaging (TDI) and strain/strain rate imaging 
(SRI) being the most common of them. LV diastolic dysfunction, easily 
detected by TDI at exercise stress, may be the earliest sign of diabetes-
induced LV dysfunction. Thus, normal echocardiographic studies at 
rest are unable detect presence of diabetic cardiomyopathy. The latest 
studies illustrate that diastolic dysfunction develops earlier than 
systolic dysfunction in diabetic hearts. However, Ernande et al. [56] 
recently reported that systolic longitudinal strain rate was abnormal 
in 28% of diabetic patients with normal diastolic function and in 
35% of those with diastolic dysfunction. Assessment of interstitial 
fibrosis by integrated backscatter or Gd-enhancement of cardiac MRI is 
possible, but its diagnostic value has not yet been established [57-60]. 
A promising novel approach to diagnosis of diabetic cardiomyopathy 
is analysis of metabolic changes associated with the myocardium by 
31P-MRS and by 1H-MRS (magnetic resonance spectroscopy [MRS]). 
A parameter for detection of energy charge, the PCr/ATP ratio, is found 
to be reduced in the myocardium of diabetic patients when compared 
with that of control subjects. The newer studies using 1H-MRS have 
demonstrated that increase in myocardial triglyceride content (also 
known as; myocardial steatosis) was also found to be associated with 
LV diastolic dysfunction in diabetic patients. It is worthwhile to mention 
here that, myocardial steatosis was observed to be associated with 
LV longitudinal strain and with systolic/diastolic strain rates also, as 
determined by two-dimensional speckle tracking imaging in patients 
with uncomplicated diabetes mellitus. The possibility that myocardial 
Safety profile
Tolerability
Number of significant drug interactions
Cost
Line of treatment and 
number of trials
Type of clinical trial Name of the 
drug
Study of the trial References
First-line treatment (three 
or more randomized 
clinical trials)










This study examined the use of gabapentin extended 
release which is not currently commercially available
This was a randomized control trial of venlafaxine 
v/s imipramine in neuropathic pain and included 
15 patients with painful diabetic neuropathy
[23-31]
Second line treatment (two 




trials on different 
Anticonvulsant 
drugs (Supported by 
evidence from two 
or more randomized 




This study examined use of venlafaxine extended 
release
This was a double-blind, randomized 
placebo-controlled trial in diabetic neuropathy which 
found that both valproate and a combination of 
valproate plus glyceryl trinitrate spray improved pain 
control
[32,33]
Third line treatment (two 
or more randomized 
clinical trials but with 
conflicting data.)
Supportive randomized 
controlled trials as 






A randomized control trial was carried out comparing 
lamotrigine with amitriptyline and placebo for the 
treatment of painful diabetic neuropathy
Another study with conflicting results examined 
lamotrigine dose up to 400 mg/day and dosing at 
200 mg/day for neuropathic pain
A study examined oxcarbazepine dosing at 600, 
1200, and 1800 mg/day. The results were not 
statistically significant in respect to efficacy variable, 
but improvement in pain was observed in patients 
receiving 1200 or 1800 mg/day in comparison to 
placebo and 600 mg/day group
Two more studies were studies were carried out which 
examined oxcarbazepine dosing at 1800 mg/day and 
1200 mg/day the latter, however, showed conflicting 
results
A randomized, placebo-controlled trial was conducted, 
and a trial with conflicting results was also carried out
[34-41]
Table 1: Criteria of trials
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steatosis is a specific marker of the diabetic cardiomyopathy warrants 
further investigation [61-63]. The various clinical and pathological 
changes observed in diabetic cardiomyopathy can be diagnosed by 
different sophisticated techniques as mentioned in Table 2 [64].
CLINICAL STUDIES FOR PREVENTION AND TREATMENT OF 
DIABETIC CARDIOMYOPATHY
Although the high prevalence of subclinical myocardial dysfunction has 
been reported in the early stage of Type 1 diabetes mellitus (T1DM), 
clinically relevant heart failure is relatively rare in this type of diabetes. 
In an observational study conducted by Torffvit et al.; 2005, 462 T1DM 
patients without a previous history of heart disease were took under 
observation, and it was found that only 17 patients (3.7%) developed 
heart failure during 12-years follow-up period. The patients who 
developed heart failure in this cohort were older in age (35±9 years) 
and had been long-term diabetic, hypertensive, had albuminuria and 
retinopathy as compared to patients who did not have heart failure. 
In contrast, heart failure develops more commonly in patients with 
T2DM, as being associated with other predisposing factors, such as 
hypertension and leading to heart failure. Thus, glycemic control alone 
is not sufficient for the prevention of diabetic cardiomyopathy [65-67].
A number of clinical trials have been conducted to evaluate the impact 
of glycemic control on the prevention of cardiovascular events in T2DM. 
However, endpoints in the studies were atherosclerotic cardiovascular 
events and death, leaving non-ischemic heart failure not specifically 
determined. A recently published meta-analysis by Turnbull et al.; 2009, 
including a total of 27,049 subjects in the UKPDS 33 (UK Prospective 
Diabetes Study 33), ACCORD, ADVANCE, and VADT trials showed that 
mortality was not affected by intensive glycemic control, with hazard 
risks of 1.10 for cardiovascular death (p<0.05; 0.84-1.42) and 1.04 for 
all-cause death (p<0.05: 0.90-1.20) [68].
These elucidations appear to contradict the notion, which tight glycemic 
control is beneficial for prevention of diabetic cardiomyopathy. 
However, these results do not eliminate the possibility that intensive 
glycemic control commenced at an earlier stage of diabetes together 
with control of other risk factors can prevent heart failure in diabetic 
patients. This speculation is supported by a few evidence. First, clinical 
studies using TDI showed that glycemic control improved LV diastolic 
function in T2DM [69,70].
Second, the Steno-2 trial showed that simultaneous control of glycemia, 
hypertension, and dyslipidemia significantly reduced cardiovascular 
events and mortality in T2DM patients. Third, a recent meta-analysis 
of clinical trials on hypertension indicates that diabetes increases the 
incidence of heart failure by more than fourfold in hypertensive patients. 
Whether incidence and/or outcome of heart failure differ depending 
on the type of hypoglycemic agent selected for hyperglycemia control 
remains unclear. This issue has not been addressed by a prospective 
randomized clinical trial. Eurich et al.; 2007 conducted observational 
cohort studies and retrospective analyses of registered patients, and 
reported that use of metformin is associated with low incidence of heart 
failure compared with other glycemia control regimens. Furthermore, 
clinical outcomes in diabetic patients with heart failure were better 
in groups treated with metformin as reported in a trial conducted by 
Aguilar et al. on metformin-treated and metformin-untreated groups 
of diabetic patients with heart failure and showed that mortality was 
lower in the metformin-treated group. In contrast with metformin, 
thiazolidinedione (TZD) has been shown to increase the incidence of 
“heart failure” in diabetes compared with sulfonylurea. Unfortunately, 
it is not clear whether the increase in “heart failure” by TZD is due to 
worsening of LV function or just retention of fluids [71-78].
In fact, recent studies carried out by Horio et al.; 2005 and van der 
Meer et al.; 2009 have suggested a favorable effect of TZD on cardiac 
function. Pioglitazone was used for a 6 month treatment regimen 
followed by which diastolic function was improved as assessed using 
Doppler echocardiography in hypertensive patients in proportion to 
the amelioration of insulin resistance. The same duration of treatment 
with pioglitazone was also reported to improve diastolic function and 
LV compliance assessed using MRI in uncomplicated T2DM patients. 
It is critical; however, that improvement in the function could not be 
proven by treatment-related myocardial metabolic change diagnosed 
by positron emission tomography and MRS alone. Therefore, 
prospective clinical trials are necessary to clarify efficacies and explain 
the pharmacological role of hypoglycemic drugs in the prevention of 
diabetic cardiomyopathy [79-80].
CURRENT TREATMENT APPROACH FOR DIABETIC 
CARDIOMYOPATHY
The approach for the treatment of diabetic cardiomyopathy is based 
on four fundamentals: Lifestyle changes, maintenance of blood 
glucose level, modification of risk factors for cardiovascular disease, 
and the treatment of heart failure. However, all the above-mentioned 
criteria revolve around the management of cardiomyopathy to 
provide symptomatic relief to the patient rather than aiming to cure 
the root problem. Hence, we need to research other unconventional 
approaches to treat this complication of diabetes. Herbal drugs offer a 
good thrust area for this purpose as they are free from unwanted side 
effects and hold the extreme unexplored potential to cure diabetes and 
its related complications. Thus, the latter part of this review focuses 
on the herbal treatment approach for diabetic cardiomyopathy which 
demands illustrative research to find its place in the current clinical 
scenario.
Lifestyle modification
Smoking cessation, healthy eating habits, reduction in body weight and 
aerobic exercise are the cornerstones in terms of lifestyle change. It 
has been shown in people with diabetes mellitus type 2 that, following 
reduction of their body weight and increased aerobic activity, the 
incidence of diabetic cardiomyopathy decreased significantly [81-83].
MANAGEMENT OF HYPERGLYCAEMIA AND OTHER RISK FACTORS
The modern therapeutic arsenal has several effective medications to 
treat diabetes, such as metformin, sulfonylureas, glitazones, insulin, and 
some modern drugs, such as GLP1 agonists and antagonists of DPP4. 
Although these drugs appear effective in treating diabetes in people 
without concomitant heart failure, in patients with heart failure there 
are some limitations.
The classic example is metformin, which has been previously 
contraindicated in heart failure because of the risk of lactic acidosis. 
However, in clinical practice and use, it turns out that the risk of 
lactic acidosis associated with metformin in people with diabetes and 
heart failure is not so great. In addition, metformin can upregulate 
cardiomyocyte autophagy, which plays an important role in the 
prevention of diabetic cardiomyopathy in animal models. Metformin 
Table 2: Diagnostic clues of diabetic cardiomyopathy 
Structural changes
LV hypertrophy assessed by 2D echocardiography or CMR
Increased integrated backscatter in the LV (septal and posterior 
wall)
Late Gd-enhancement of the myocardium in CMR
Functional changes
LV diastolic dysfunction assessed by pulsed Doppler 
echocardiography and TDI
LV systolic dysfunction demonstrated by TDI/SRI
Limited systolic and/or diastolic functional reserve assessed by 
exercise TDI
Metabolic changes
Reduced cardiac PCr/ATP detected by 31P-MRS
Elevated myocardial triglyceride content detected by 1H-MRS
CMR: Cardiac magnetic resonance imaging, 2D two dimensional, LV: Left 
ventricular, MRS: Magnetic resonance spectroscopy, SRI strain/SRI: Strain/
strain rate imaging, TDI: Tissue Doppler imaging [65]
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has also been reported to reduce mortality rates and lower all-cause 
hospital admissions [84-88].
Treatment of heart failure
According to the 2013 ESC Guidelines on diabetes, pre-diabetes, 
and cardiovascular diseases, three neurohormonal antagonists—
an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin 
receptor blocker (ARB), a beta-blocker, and a mineralocorticoid 
receptor antagonist (MRA)—are the most important pharmacological 
agents for the treatment of all patients with heart failure and reduced 
LV ejection fraction, including those with diabetes mellitus. They are 
usually combined with a diuretic for relieving congestion and may also 
be supplemented by ivabradine.
ACE-I and ARB
An ACE-I is indicated in diabetes mellitus type 2 and heart failure, 
since it improves symptoms and reduces mortality [89-92]. The 
beneficial effects of ARBs are equivalent to those of ACE-I, according 
to subgroup analyses of clinical trials, and therefore, an ARB can be 
used as an alternative in ACE intolerant patients. When ACE-I and 
ARBs are used in patients with diabetes mellitus, monitoring of kidney 
function and potassium is mandatory, since nephropathy is a frequent 
occurrence [93].
Beta-blockers
Beta-blockers are the standard drugs for patients with systolic heart 
failure [94,95]. As reported by Deedwania et al.; 2005, a subgroup 
analysis of the MERIT-HF trial, showed that beta-blockers reduce 
mortality and hospital admissions and improve symptoms, significantly 
in both, diabetes mellitus type 2 and non-diabetic patients. Beta-
blockers recommended in heart failure and diabetes mellitus type 2 
are metoprolol succinate in the slow release form (MERIT-HF), 
bisoprolol (Cardiac Insufficiency Bisoprolol Study II), and carvedilol 
(carvedilol prospective randomized cumulative survival and carvedilol 
or metoprolol European Trial) [96-99]. Adverse effects of beta-blockers 
in patients with diabetes mellitus type 2 and heart failure include 
hypoglycemia, especially with non-cardioselective regimens, and 
negative metabolic effects (hypoglycemia, dyslipidemia and decreased 
insulin sensitivity) [100,102].
MRA
An MRA is recommended for all patients with persisting symptoms 
(New York Heart Association Class II-IV) and an LV ejection 
fraction =35%, despite treatment with an ACE-I (or, if not tolerated, an 
ARB) and a beta-blocker, to reduce the risk of heart failure hospitalization 
and premature death (Class IA). The benefit of spironolactone and 
eplerenone on mortality did not differ between patients with or without 
diabetes mellitus type 2 and heart failure. Monitoring of kidney function 
and potassium is mandatory, due to the increased risk of nephropathy in 
patients with diabetes mellitus [64,103].
Diuretics
These drugs are useful for the relief of dyspnea and edema in heart 
failure with fluid retention, irrespective of the ejection fraction, 
although there is no evidence of a reduction in mortality or morbidity. 
Loop diuretics are recommended, rather than thiazides, because of 
their better glycemic profile [104].
Ivabradine
The SHIFT trial, involving 6558 patients with heart failure, in sinus 
rhythm and with heart rate =70 bpm (3241 on ivabradine; 30% with 
diabetes mellitus type 2), demonstrated that ivabradine significantly 
reduced cardiovascular deaths and hospital admissions for worsening 
heart failure. The beneficial difference was similar in a pre-specified 
subgroup analysis of patients with and without diabetes mellitus. 
Finally, the presence of diabetes mellitus is not a contraindication for 
cardiac resynchronization therapy and/or cardiac transplantation 
in patients with advanced systolic heart failure. Heart failure with 
preserved LV ejection fraction is a primary phenotype in diabetes, 
and therapy to improve the prognosis of this type of heart failure is in 
general still under intensive investigation [105].
SELECTED HERBAL DRUGS AND NATURAL COMPOUNDS FOR 
DIABETIC NEUROPATHY AND CARDIOMYOPATHY
Treatment of diabetic cardiomyopathy and neuropathy is based on the 
general therapeutic rules of heart failure and pain respectively; therefore, 
further investigation studies are required for prevention and treatment 
of these two complex conditions. With increased significance of the 
two aforesaid conditions, this review has summarized the associated 
structural, functional and metabolic changes to provide a novel and 
more targeted therapies free of side effects. With this view, some lesser 
known, potentially strong herbal therapies for diabetic cardiomyopathy 
and neuropathy are illustrated. These have huge potential to improve 
the quality of life of patients. As the mechanisms responsible for diabetic 
cardiomyopathy and neuropathy continue to be elucidated, it is hoped 
that these insights will provide the impetus for novel therapies that 
reduce the risk of heart failure and debilitating pain in individuals 
with diabetes mellitus and are free of the hazardous side effects which 
currently in use medications pose to diabetic patients [106].
Flavonoids form a class of benzo-gamma pyrone derivatives that are 
pharmacologically very potent. Quercetin, for instance, found most 
abundantly among dietary flavonols, is a potent antioxidant due to 
its all the right structural features for free radical scavenging activity. 
It is evident that the flavonoids play an important role in the various 
types of metabolic activities of life. They have also been suggested to 
play a protective role in liver diseases, cataracts, and cardiovascular 
diseases [107].
Curcumin is known to have shown a neuroprotective effect in multiple 
animal models and has great potential for the prevention or treatment 
of age-related neuropathy arising from chronic diabetes. Curcumin, 
being pharmacologically safe and effective, is a potential compound 
for treatment and prevention of a wide spectrum of human diseases. 
Curcumin has been known to have a potential role in reducing serum 
glucose level, sciatic neuronal proteins, neuronal protein carbonyls, 
nociceptive, motor coordination, nerve conduction velocity, Aldose 
reductase COX, PG peroxidase and Na+ K+ ATPase activity [108].
Acacia arabica: (Babhul)
It is a wild growing plant, found all over India. The plant extract has an 
antidiabetic effect, behaving as a secretagouge stimulating the insulin 
release. It induces hypoglycemia in control rats but not in alloxan-
treated animals. Powdered seeds of A. arabica when administered (2, 3 
and 4 g/kg body weight) to normal rabbits induced hypoglycemic effect 
by initiating release of insulin from pancreatic beta cells [109].
Aegle marmelos: (Bengal Quince, Bel or Bilva)
The aqueous extract of leaves of A. marmelos when administered to 
alloxanized rats, improved digestion and reduced blood sugar level, 
urea, and serum cholesterol, as compared to control. Along with 
exhibiting antidiabetic activity, this extract also prevented peak rise in 
blood sugar at 1h in oral glucose tolerance test [110].
Azadirachta indica: (Neem)
A. indica, commonly known as Neem, Nimtree, and Indian Lilac is a 
tree of family Meliaceae. The genus Azadirachta is known to have 
two species of which A. indica is native to India. The hydroalcoholic 
extracts of this plant showed antihyperglycemic activity in 
streptozotocin-induced diabetic rats, and this effect was observed due 
to increase in glucose uptake and glycogen deposition in isolated rat 
hemidiaphragm [109,110]. Apart from having anti-diabetic activity, 
this plant has also been reported to possess antibacterial, antimalarial, 
antifertility, hepatoprotective, and antioxidant properties [112].
Eugenia jambolana: (Indian gooseberry, jamun)
E. jambolana is used as household remedy for diabetes in India, specifically 
the decoction of its kernels. Hence, it forms a major constituent of 
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many herbal formulations for diabetes. Antihyperglycemic effect of 
aqueous and alcoholic extract as well as lyophilized powder shows 
hypoglycemic activity. This varies with the different level of diabetes. As 
found in a study by Chattopadhyay et al., in mild diabetes (plasma sugar 
>180 mg/dl) it shows 73.51%reduction, whereas in moderate (plasma 
sugar >280 mg/dl) and severe diabetes (plasma sugar >400 mg/dl) it is 
reduced to 55.62% and 17.72%, respectively. The extract of jamun pulp 
showed the hypoglycemic activity in streptozotocin-induced diabetic 
mice within 30 min of administration, whereas the seed of the same 
fruit required 24 hrs. The oral administration of the extract resulted 
in increased serum insulin level in diabetic rats. Insulin secretion was 
found to be stimulated on incubation of plant extract with isolated islets 
of Langerhans from normal as well as diabetic animals. These extracts 
also inhibited insulinase activity from liver and kidney [113].
Tinospora cordifolia: (Guduchi)
It is a large, glabrous, deciduous climbing shrub belonging to the 
family Menispermaceae. It is commonly known as Guduchi or Giloe. 
T. cordifolia is widely used in Indian Ayurvedic medicine for treating 
diabetes mellitus. Although the aqueous extract at a dose of 400 mg/kg 
could show a significant antihyperglycemic effect in different animal 
models, its effect was equivalent to only one unit/kg of insulin. It is 
reported that the daily administration of either alcoholic or aqueous 
extract of T. cordifolia decreases the blood glucose level and increases 
glucose tolerance in rodents.
CONCLUSION
Medicinal plants are being scientifically explored once again for the 
treatment of diabetes. Many conventional drugs have been derived 
from prototypic molecules in medicinal plants. Metformin exemplifies 
an efficacious oral glucose-lowering agent. Its development was based 
on the use of Galega officinalis to treat diabetes. G. officinalis is rich in 
guanidine, the hypoglycemic component. Because guanidine is too toxic 
for clinical use, the alkyl biguanides synthalin A and synthalin B were 
introduced as oral anti-diabetic agents in Europe in the 1920s but were 
discontinued after insulin became more widely available. However, 
experiment with guanidine and biguanides lead to the development of 
metformin. Till date, over 400 traditional plant treatments for diabetes 
have been reported, although only a small number of these have received 
a scientific and medical evaluation to assess their efficacy. The World 
Health Organization Expert Committee on Diabetes has recommended 
that traditional medicinal herbs be further investigated. The major 
hindrance in the amalgamation of herbal medicine in modern medical 
practices is a lack of scientific and clinical data proving their efficacy 
and safety. There is a need for conducting clinical research in herbal 
drugs, developing simple bioassays for biological standardization, 
pharmacological and toxicological evaluation, and developing various 
animal models for toxicity and safety evaluation. It is also important to 
extract the active components from these plant extracts.
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